Sign in

or Register now

MultipleSclerosisCentral.com

See all of our health sites at www.HealthCentral.com
Sunday, September 7, 2008

Pregnancy hormone may help with brain injury

By Will Boggs, MD Tuesday, May. 8, 2007; 5:27 PM

NEW YORK (Reuters Health) - In adult patients with traumatic brain injury, treatment with the pregnancy-supporting hormone progesterone may improve outcomes -- especially in cases of moderate injury -- according to a report in the Annals of Emergency Medicine.

"I'd like physicians to appreciate the excitement and hope of finally identifying an agent for the treatment of traumatic brain injury -- and possibly other neurological injuries such as stroke, spinal cord injury, and multiple sclerosis," Dr. David W. Wright told Reuters Health. "No current therapy exists that improves the outcome of brain injury patients."

Wright from the School of Medicine at Emory University, Atlanta, and colleagues conducted a trial to assess the safety and potential benefit of administering intravenous progesterone to 100 patients with brain injury. Patients were randomly assigned to receive progesterone or inactive "placebo."

Brain pressure remained stable in progesterone-treated patients, the authors report, whereas it tended to increase in the placebo group. Increases in brain pressure raise the risk of brain damage.

Progesterone patients remained in coma longer than placebo patients, the report indicates, but just 13 percent of progesterone-treated patients died within 30 days of injury compared with 30.4 percent of placebo patients.

The reduction in death risk seen with progesterone was most prominent among patients with more severe brain injury, the investigators state.

On the other hand, at 30 days, survivors of severe brain injury who had received placebo were slightly less disabled than those who had received progesterone, the report indicates. Patients with moderate traumatic brain injury who had received progesterone were significantly less disabled than those who had received placebo.

Side effects were comparable between the progesterone and placebo groups, the researchers note.

"We are trying to gather enough data to make sense of the 1 year outcomes," Wright said. "So far, we have only been able to assess about 40 percent of the enrolled subjects."

SOURCE: Annals of Emergency Medicine, April 2007.


Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Ask a Question

Get answers from our experts and community members.

Answer a Question

Solumedrol Drip

Answer This View all questions >
Free Newsletter
Get weekly updates, news alerts and more on Multiple Sclerosis and related health conditions.